---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032831"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:48:03.580377+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024

## Summary
- NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.
- ONP-002 cleared FDA-required cardiotoxicity and genotoxicity tests; Phase 2 trial expected to start Q4 2024 in Australia.
- Improved intranasal formulation increases ONP-002 per dose by 4X; automated device prototype for use in acute concussion completed.
- Closed public offering raising ~$1.1M to fund ONP-002 development and corporate needs.
- Appointed Dr. Peacock as Chief Clinical Officer and Dr. Kelly as Chief Medical Officer for Phase 2 trial.

## SEC filing metadata
- accession: 0001493152-24-032831
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224032831/0001493152-24-032831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224032831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032831
- JSON: https://secwatch.observer/filing/0001493152-24-032831.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.